摘要
目的:评价盐酸伊托必利治疗功能性消化不良的疗效和安全性。方法:将67例功能性消化不良患者随机分为治疗组34例,给予口服盐酸伊托必利50mg,餐前口服,每日3次;对照组33例,给予多潘立酮10mg,餐前口服,每日3次。疗程均为4周。结果:两组患者功能性消化不良的症状均显著缓解,疗效相近,但餐后饱胀的改善作用治疗组优于对照组。结论:盐酸依托必利是治疗功能性消化不良疗效较好的新一代胃肠道促动力药。
Objective:To evaluate the clinical efficacy and safety of Itopride hydrochloride on functional dyspepsia.Meth-ods:67 patcients with functional dyspepsia were randomly divided into the test group(n=34)and the control group(n=33) to receive Itopride hydrochloride 50 mg, po, tid, and Domperidone 10 mg, po, tid, respectively for 4 weeks.Results:The symptoms of all patients were improved significantly, and there was no statistically significant difference in symptom scores between the two groups.But the improvement of bloating after meal in the test group was superior to that in the control group.Conclusion:Itopride hydrochloride is a new safety efficacious drug for treating functional dyspepsia.
出处
《中国医药导报》
CAS
2009年第12期75-76,共2页
China Medical Herald